---
title: "Hypofractionated versus Conventional Salvage Radiotherapy After Prostatectomy: Phase III JCO Trial"
id: "pubmed-42641124"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42641124"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42641124/"
doi: "10.1200/JCO-25-02234"
published_at: "2026-11-20T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Hypofractionated versus Conventional Salvage Radiotherapy After Prostatectomy: Phase III JCO Trial
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42641124
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42641124/)
- **DOI:** [10.1200/JCO-25-02234](https://doi.org/10.1200%2FJCO-25-02234)
- **Published At:** 2026-11-20T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- Phase III randomized trial compared **hypofractionated radiotherapy** (65 Gy in 26 fractions) with conventional RT (66 Gy in 33 fractions) for salvage treatment after radical prostatectomy. - 316 patients with intermediate- to high-risk disease were randomized between 2019 and 2021; RT targeted the prostate bed and elective pelvic nodal irradiation was allowed at investigator discretion. - Intensity-modulated RT with daily image guidance was used across both arms; endorectal balloons were employed in 186 patients (63.1%). - Androgen deprivation therapy was given to 151 patients (51.2%). - Median pre-RT PSA was 0.36 ng/mL (IQR, 0.24–0.49 ng/mL). - After median follow-up of 52.6 months, 4-year **biochemical progression-free survival** (bPFS) was 80.1% for HYPO and 78.1% for CONV; investigators reported no superiority of HYPO for the primary end point. - Four-year distant metastasis-free survival and prostate cancer-specific survival were similar between arms (DMFS 91.7% v 91.0%; CSS 100% v 100%). - Cumulative 4-year grade ≥2 gastrointestinal toxicity was higher in the HYPO arm (7.9% v 0.7%), occurring mainly among patients who did not have an **endorectal balloon**; reported cases had resolved by last follow-up. - Patient-reported quality-of-life measures were comparable between groups. - The trial team concluded hypofractionated salvage RT is a viable alternative given comparable oncologic and quality-of-life outcomes; they noted further research is required to clarify the protective effect of endorectal balloons on GI toxicity. - Trial registration: ClinicalTrials.gov NCT03920033.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42641124/#article-details) ### NIH Websites Are Changing * [Get the Latest Updates and FAQs on the transition](https://www.nih.gov/web-modernization) * Per [Executive Order 14434](https://www.whitehouse.gov/presidential-actions/2026/09/inaugurating-the-era-of-super-intelligence/), federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition. ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42641124%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42641124/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42641124/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42641124/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42641124/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42641124/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42641124/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42641124%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42641124%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42641124/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42641124/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42641124/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42641124/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Full text links [![Atypon full text link](https://cdn.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--ascopubs.org-pb-assets-pubmed-JCO_125x30.png) Atypon ](https://ascopubs.org/doi/10.1200/JCO-25-02234?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed "See full text options at Atypon") [ Full text links ](https://pubmed.ncbi.nlm.nih.gov/42641124/) ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42641124/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42641124/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42641124/#abstract) * [Similar articles](https://pubmed.ncbi.nlm.nih.gov/42641124/#similar) * [ Publication types ](https://pubmed.ncbi.nlm.nih.gov/42641124/#publication-types) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42641124/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42641124/#substances) * [ Associated data ](https://pubmed.ncbi.nlm.nih.gov/42641124/#supplemental-data) * [Related information](https://pubmed.ncbi.nlm.nih.gov/42641124/#related-links) * [ LinkOut - more resources ](https://pubmed.ncbi.nlm.nih.gov/42641124/#linkout) Title & authors Abstract Similar articles Publication types MeSH terms Substances Associated data Related information LinkOut - more resources Clinical Trial J Clin Oncol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Clin+Oncol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Clin+Oncol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42641124/) . 2026 Nov 20;44(33):3227-3236. doi: 10.1200/JCO-25-02234. Epub 2026 Aug 25. # Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial [Youngju Song](https://pubmed.ncbi.nlm.nih.gov/?term=Song+Y&cauthor_id=42641124)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#full-view-affiliation-1 "Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea."), [Won Park](https://pubmed.ncbi.nlm.nih.gov/?term=Park+W&cauthor_id=42641124)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#full-view-affiliation-2 "Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea."), [Hongryull Pyo](https://pubmed.ncbi.nlm.nih.gov/?term=Pyo+H&cauthor_id=42641124)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#full-view-affiliation-2 "Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea."), [Yeon Joo Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+YJ&cauthor_id=42641124)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#full-view-affiliation-1 "Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea."), [Hanjong Ahn](https://pubmed.ncbi.nlm.nih.gov/?term=Ahn+H&cauthor_id=42641124)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#full-view-affiliation-3 "Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#full-view-affiliation-4 "Department of Urology, Kangwon National University Hospital, Chuncheon-si, Republic of Korea."), [Hwa Jung Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+HJ&cauthor_id=42641124)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#full-view-affiliation-5 "Department of Medical Informatics & Statistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea."), [Young Seok Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+YS&cauthor_id=42641124)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#full-view-affiliation-1 "Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.") Affiliations Expand ### Affiliations * 1 Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. * 2 Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. * 3 Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. * 4 Department of Urology, Kangwon National University Hospital, Chuncheon-si, Republic of Korea. * 5 Department of Medical Informatics & Statistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. * PMID: **42641124** * DOI: [ 10.1200/JCO-25-02234 ](https://doi.org/10.1200/jco-25-02234) Item in Clipboard Clinical Trial # Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial Youngju Song et al. J Clin Oncol. 2026. Show details Display options Display options Format Abstract PubMed PMID J Clin Oncol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22J+Clin+Oncol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J+Clin+Oncol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42641124/) . 2026 Nov 20;44(33):3227-3236. doi: 10.1200/JCO-25-02234. Epub 2026 Aug 25. ### Authors [Youngju Song](https://pubmed.ncbi.nlm.nih.gov/?term=Song+Y&cauthor_id=42641124)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#short-view-affiliation-1 "Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea."), [Won Park](https://pubmed.ncbi.nlm.nih.gov/?term=Park+W&cauthor_id=42641124)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#short-view-affiliation-2 "Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea."), [Hongryull Pyo](https://pubmed.ncbi.nlm.nih.gov/?term=Pyo+H&cauthor_id=42641124)[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#short-view-affiliation-2 "Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea."), [Yeon Joo Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+YJ&cauthor_id=42641124)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#short-view-affiliation-1 "Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea."), [Hanjong Ahn](https://pubmed.ncbi.nlm.nih.gov/?term=Ahn+H&cauthor_id=42641124)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#short-view-affiliation-3 "Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.")[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#short-view-affiliation-4 "Department of Urology, Kangwon National University Hospital, Chuncheon-si, Republic of Korea."), [Hwa Jung Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+HJ&cauthor_id=42641124)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#short-view-affiliation-5 "Department of Medical Informatics & Statistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea."), [Young Seok Kim](https://pubmed.ncbi.nlm.nih.gov/?term=Kim+YS&cauthor_id=42641124)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42641124/#short-view-affiliation-1 "Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.") ### Affiliations * 1 Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. * 2 Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. * 3 Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. * 4 Department of Urology, Kangwon National University Hospital, Chuncheon-si, Republic of Korea. * 5 Department of Medical Informatics & Statistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. * PMID: **42641124** * DOI: [ 10.1200/JCO-25-02234 ](https://doi.org/10.1200/jco-25-02234) Item in Clipboard Full text links Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract **Purpose:** To compare hypofractionated radiotherapy (RT) with conventional RT for treating biochemical recurrence following radical prostatectomy. **Methods:** Between 2019 and 2021, 316 patients with intermediate- to high-risk prostate cancer were randomly assigned to receive salvage RT with either 65 Gy in 26 fractions (hypofractionated RT, HYPO) or 66 Gy in 33 fractions (conventional RT, CONV). RT was delivered to the prostate bed, with elective pelvic nodal irradiation performed at the discretion of radiation oncologists. Intensity-modulated RT with daily image guidance was used. The primary end point was biochemical progression-free survival (bPFS). Secondary end points included distant metastasis-free survival (DMFS), prostate cancer-specific survival (CSS), toxicity profiles, and patient-reported quality-of-life. **Results:** One hundred fifty-one patients (51.2%) received androgen deprivation therapy, and 202 (68.5%) underwent elective nodal irradiation. Endorectal balloons were used in 186 men (63.1%). The median pre-RT prostate-specific antigen level was 0.36 ng/mL (IQR, 0.24-0.49 ng/mL). After a median follow-up of 52.6 months, the 4-year bPFS rates were 80.1% and 78.1% in the HYPO and CONV arms, respectively. There were no significant differences in DMFS (91.7% _v_ 91.0%) and CSS (100% _v_ 100%). The 4-year cumulative incidence of grade ≥2 GI toxicity was higher in the HYPO arm (7.9% _v_ 0.7%), predominantly among patients without an endorectal balloon; all cases were resolved by the last follow-up. Patient-reported quality-of-life outcomes were comparable. **Conclusion:** bPFS was not superior in the HYPO arm at 4 years. However, given the comparable oncologic outcomes, toxicity profiles, and quality-of-life measures, hypofractionated RT may be considered a viable alternative in the salvage setting. Further research is needed to determine whether the use of an endorectal balloon reduces GI toxicity. **Trial registration:** ClinicalTrials.gov [NCT03920033](http://clinicaltrials.gov/show/NCT03920033 "See in ClinicalTrials.gov"). [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [ Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience. ](https://pubmed.ncbi.nlm.nih.gov/33980277/) Murgic J, Jaksic B, Prpic M, Kust D, Bahl A, Budanec M, Prgomet Secan A, Franco P, Kruljac I, Spajic B, Babic N, Kruslin B, Zovak M, Zubizarreta E, Rosenblatt E, Fröbe A.Murgic J, et al.Radiat Oncol. 2021 May 12;16(1):88. doi: 10.1186/s13014-021-01808-3.Radiat Oncol. 2021.PMID: 33980277Free PMC article.Clinical Trial. * [ Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. ](https://pubmed.ncbi.nlm.nih.gov/33444529/) Fransson P, Nilsson P, Gunnlaugsson A, Beckman L, Tavelin B, Norman D, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Björnlinger K, Seke M, Agrup M, Zackrisson B, Kjellén E, Franzén L, Widmark A.Fransson P, et al.Lancet Oncol. 2021 Feb;22(2):235-245. doi: 10.1016/S1470-2045(20)30581-7. Epub 2021 Jan 11.Lancet Oncol. 2021.PMID: 33444529Clinical Trial. * [ Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. ](https://pubmed.ncbi.nlm.nih.gov/26867889/) Lewis SL, Patel P, Song H, Freedland SJ, Bynum S, Oh D, Palta M, Yoo D, Oleson J, Salama JK.Lewis SL, et al.Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):605-11. doi: 10.1016/j.ijrobp.2015.11.025. Epub 2015 Dec 2.Int J Radiat Oncol Biol Phys. 2016.PMID: 26867889 * [ Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. ](https://pubmed.ncbi.nlm.nih.gov/34953525/) Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators.Attard G, et al.Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23.Lancet. 2022.PMID: 34953525Free PMC article. * [ Salvage radiotherapy with volumetric modulated arc therapy (VMAT) for recurrent prostate cancer after high-intensity focused ultrasound (HIFU): A large French retrospective series and literature review. ](https://pubmed.ncbi.nlm.nih.gov/39681174/) Baude J, Teyssier C, Barbier V, Tremeaux JC, Azélie C, Lépinoy A, Henry PC, Bailly V, Lescut N, Lagneau E, Schipman B.Baude J, et al.Radiother Oncol. 2025 Feb;203:110665. doi: 10.1016/j.radonc.2024.110665. Epub 2024 Dec 15.Radiother Oncol. 2025.PMID: 39681174Review. [ See all similar articles ](https://pubmed.ncbi.nlm.nih.gov/?linkname=pubmed_pubmed&from_uid=42641124) ## Publication types * Randomized Controlled Trial Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Randomized+Controlled+Trial%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Randomized+Controlled+Trial) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42641124/) * Clinical Trial, Phase III Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Clinical+Trial%2C+Phase+III%22%5Bpt%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih
## Related Clinical Research

- [COMMD1 in Cancer: Dual Roles, Mechanisms, and Translational Targets](https://medichelpline.com/clinical-feed/pubmed-43059391.md) (DOI: 10.3892/or.2026.9224)
- [USP8 inhibition degrades RICTOR to block mTORC2 and suppress prostate cancer](https://medichelpline.com/clinical-feed/pubmed-43050551.md) (DOI: 10.1126/sciadv.aeh0679)
- [Gland MRI Radiomics Predicts Time to Pathologic Progression on Prostate Cancer Active Surveillance](https://medichelpline.com/clinical-feed/medrxiv-6-automated-gland-mri-radiomics-for-predicting-time-to-pathologic-progression.md)
- [Germline genomic score P-CARE adds risk information beyond PSA for short- and long-term prostate c](https://medichelpline.com/clinical-feed/medrxiv-22-additional-value-of-germline-genomic-scores-beyond-prostate-specific-antigen.md)
- [ESMO Congress 2026: Updates on ADCs, bispecifics and RIPTACs](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-from-the-esmo-congress-2026.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.